Replimune Group (NASDAQ:REPL) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research note published on Monday morning, Benzinga reports. The firm currently has a $17.00 price target on the stock.

Several other brokerages also recently issued reports on REPL. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a buy rating and a $17.00 target price on the stock. Roth Capital raised shares of Replimune Group to a strong-buy rating in a research note on Tuesday, August 27th. JPMorgan Chase & Co. cut their target price on shares of Replimune Group from $17.00 to $14.00 and set an overweight rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an outperform rating and set a $16.00 target price on shares of Replimune Group in a research note on Thursday, June 6th. Finally, Barclays boosted their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an overweight rating in a research note on Friday, June 7th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $16.20.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $10.46 on Monday. Replimune Group has a one year low of $4.92 and a one year high of $18.12. The stock has a fifty day moving average of $10.15 and a 200-day moving average of $8.37. The company has a market capitalization of $714.63 million, a PE ratio of -3.23 and a beta of 1.22. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. As a group, equities analysts anticipate that Replimune Group will post -3.08 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently bought and sold shares of the business. Quest Partners LLC boosted its holdings in Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Algert Global LLC boosted its holdings in Replimune Group by 5.4% in the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after purchasing an additional 4,975 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.